Semaglutide News and Research

Latest Semaglutide News and Research

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Liraglutide medication can help treat type 1 diabetes

Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.

16 Jun 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin Pharmaceuticals, Inc. today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company from engaging in anticompetitive activity and breaching its diabetes collaboration agreement with Amylin.

10 Jun 2011

CLC bio, AROS partner to provide 'Total Genomic Solutions'

Today, CLC bio announced its collaboration with one of the premier European service providers, GLP and GCP certified AROS Applied Biotechnology who specialize in Total Genomic Solutions, covering all steps from extraction, sample banking, and analysis, to advanced bioinformatics using CLC bio's enterprise platform.

8 Jun 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Amylin Pharmaceuticals, Inc. today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

26 May 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly and Company has provided additional perspective in response to Amylin Pharmaceuticals, Inc.'s lawsuit filed in the United States District Court for the Southern District of California.

17 May 2011

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin Pharmaceuticals, Inc. today announced that it has filed a lawsuit against Eli Lilly and Company in the United States District Court for the Southern District of California, alleging that Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements with Amylin to maximize commercialization of exenatide.

16 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

3 May 2011

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

18 Apr 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced today new results from three studies that demonstrate the positive effects of the EndoBarrier Gastrointestinal Liner on type 2 diabetes, weight loss and other metabolic factors.

30 Mar 2011

Almac inaugurates new CLIA registered laboratory

Almac's Diagnostics business unit today announced the opening of its CLIA registered laboratory.

30 Mar 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that Nycomed, a global pharmaceutical company, headquartered in Switzerland, has submitted a Marketing Authorization Application to the European Medicines Agency for clearance to market teduglutide as a once-daily subcutaneous treatment for short bowel syndrome.

29 Mar 2011

Semaglutide News and Research

Latest Semaglutide News and Research

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Liraglutide medication can help treat type 1 diabetes

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

CLC bio, AROS partner to provide 'Total Genomic Solutions'

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Boehringer Ingelheim, Eli Lilly receive FDA approval for linagliptin to treat type 2 diabetes

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

FDA grants orphan drug status to America Stem Cell's ASC-101

GI Dynamics announces positive results from EndoBarrier studies against type 2 diabetes

Almac inaugurates new CLIA registered laboratory

Nycomed submits teduglutide MAA to EMA for SBS treatment

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Semaglutide News and Research

Latest Semaglutide News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in